Elevated expression of serum soluble ST2 in clinical relapse after stopping long-term Nucleos(t)ide analogue therapy for chronic hepatitis B

Linqing Xie 1, Guichan Liao 1, Hongjie Chen 1, Muye Xia 1, Xuan Huang 1, Rong Fan 1, Jie Peng 1, Xiaoyong Zhang 1, 2*, and Hongyan Liu 1, 2*

Abstract

Background: The virological or clinical relapse is common in chronic hepatitis B (CHB) patients after stopping long-term nucleos(t)ide analogue (NA) therapy. Soluble growth stimulation expressed gene 2 (sST2), one of the Toll-like/interleukin-1 receptor members, is involved in a variety of inflammatory processes and immune responses. However, the expression and function of serum sST2 in CHB patients after stopping NA treatment remains unknown.

Methods: A total of 91 non-cirrhotic Asian patients with CHB who discontinued NA therapy according to international guidelines were prospectively followed up to 240 weeks. All patients were divided into clinical relapse group and non-clinical relapse (including sustained virological response and only virological relapse) group according HBV DNA and ALT levels. The serum levels of sST2 of all participants were determined by ELISA and compared between each two groups.

Results: Clinical relapse occurred in 26 patients and virological relapse occurred in 57 patients. We found that there was a positive correlation between sST2 expression and HBsAg, ALT, HBV DNA, and anti-HBc levels in CHB patients after discontinuation of NA treatment. Levels of serum sST2 in clinical relapse patients showed a rising trend and most patients showed peak sST2 levels at the point of clinical relapse. Moreover, the sST2 levels of clinical relapse group at week 12, week 24 and week 48 were relatively higher than non-clinical relapse group. However, the level of sST2 at the end of treatment was not an effective biological marker for the early prediction of clinical relapse after discontinuation of long-term NA therapy.

Conclusions: In conclusion, we found that an increase in sST2 in clinical relapse patients might be associated with an inflammation-related immune response after discontinuation of NA treatment.

Trial registration: The trial was retrospectively registered at Chinese Clinical Trial Registry: ChiCTR-OOC-17013970. Registration date: December 15, 2017.

Keywords: Chronic hepatitis B, Nucleos(t)ide analogue therapy, Treatment cessation, Clinical relapse, Serum soluble ST2

* Correspondence: xiaoyzhang@smu.edu.cn; liuhongyan205628@163.com
1State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China
Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Hepatitis B virus (HBV) infection causes acute and chronic hepatitis and remains a public health problem across the world. It is estimated that 240 million people suffers HBV infection and their prevalence is geographically different. Every year, HBV-associated end-stage liver disease results in approximately one million deaths [1]. Currently, nucleos(t)ide analogue (NA) therapy is recommended by international clinical guidelines in chronic hepatitis B (CHB) patients [2, 3]. Effective suppression of HBV DNA using long-term NA therapy has been proven to delay disease progression in patients with CHB [2]. But discontinuation of NA treatment is often associated with HBV rebound and recurrence of active hepatitis after anti-HBe seroconversion [4]. Generally, HBsAg loss which links to host immune control is considered as a satisfactory biomarker for functional cure [2, 3]. However, it has been suggested that patients who achieve hepatitis B surface antigen (HBsAg) loss could discontinue NA treatment, but HBsAg loss is rare, even after long-term NA treatment [5, 6].

Currently, many studies have demonstrated that patients have very high rates of virological or clinical relapse after NA treatment cessation [5–7]. Related studies have identified that several factors could be used for predicting relapse after treatment discontinuation, including patient age [8], serum HBsAg [9], consolidation treatment time [10], residual HBV DNA levels [11], hepatitis B virus core-related antigen (HBcrAg) levels [12], and intrahepatic HBV covalently closed circular DNA (cccDNA) levels at the end of therapy [13]. There is still lack of other reliable immune biomarkers to predict early relapse after stopping long-term NA therapy.

Growth stimulation expressed gene 2 (ST2) is a member of the Toll-like/interleukin-1 receptor superfamily [14, 15]. It has two isoforms: transmembrane ST2 expressed on the cell surface and soluble ST2 (sST2) in the serum [16]. sST2 expression is elevated in several inflammatory diseases, including atopic individuals with allergic symptoms or exacerbation of asthma [17, 18], atopic dermatitis [19], rheumatoid arthritis [20, 21], ulcerative colitis, Crohn’s disease [22], and systemic lupus erythematosus [23]. In liver diseases, sST2 was reported to positively correlates with alanine aminotransferase (ALT) levels in chronic hepatitis patients [24]. And it has been proved to be a promising prognostic biomarker in HBV-related acute-on-chronic liver failure [25].

Previous studies from our group had demonstrated that after NA treatment discontinuation, a lower clinical relapse rate was observed in younger patients and in those with low end-of treatment HBsAg levels. And the persistence of off-treatment elevated HBV DNA levels were useful in the prediction of clinical relapse and may be used to guide off-treatment management [9]. Moreover, serum levels of anti-HBc might be used to select patients suitable for NA treatment discontinuation [26]. However, the expression and role of sST2 in patients after discontinuation of long-term NA therapy has yet to be explored. This prospective study investigated the expression and clinical significance of sST2 in CHB patients after cessation of long-term NA therapy.

Methods
Study subjects
Ninety-one CHB patients who enrolled in a prospective, single-center, observational study and underwent cessation of NA therapy (Chinese Clinical Trial Registry number: ChiCTR-OOC-17013970) were included in this study. Patients were recruited from Nanfang Hospital (Guangzhou, China) from November 2012 until May 2018 and provided informed consent and voluntarily entered the study cohort [27]. Patients discontinued NA therapy in accordance with the 2012 The Asian Pacific Association for the Study of the Liver (APASL) guideline [28]. The criterion of discontinuation NA therapy for CHB patients was HBeAg seroconversion, undetectable HBV DNA, and normalized ALT level, and consolidated treatment for at least 12 months or 18 months. Patients

Table 1 Demographic data and clinical characteristics

| Characteristic                        | n = 91 |
|--------------------------------------|--------|
| Baseline (end of treatment)          |        |
| Age, years                           | 35.7 ± 7.9 |
| Sex (Male: Female)                   | 75:16 |
| First-line NA therapy *              | 39 (42%) |
| Therapy duration, years              | 56.7 ± 26.2 |
| Consolidation therapy duration, months | 28 (18–46) |
| ALT level, × ULN                     | 0.5 (0.4–0.7) |
| ALT elevation, n (%)                 |        |
| < ULN                                 | 78 (86%) |
| ULN-2 × ULN                           | 12 (13%) |
| HBV DNA level, log_{10} IU/ml        | UD |
| HBsAg level, log_{10} IU/ml          | 2.9 (2.3–3.3) |
| < 100 IU/ml                          | 20 (22%) |
| 100–1000 IU/ml                       | 31 (34%) |
| > 1000 IU/ml                         | 40 (44%) |
| Start of treatment                   |        |
| HBeAg status (Positive: Negative)    | 61:30 |
| ALT elevation ×ULN                   | 5.33 ± 4.29 |
| HBV DNA log_{10} IU/ml               | 6.20 ± 1.41 |

Quantitative variables are expressed as mean values ± standard deviation (range) or median values (range). ALT Alanine aminotransferase, HBsAg Hepatitis B surface antigen, HBV Hepatitis B virus, NA Nucleos(t)ide analogue, UD Undetectable (< 20 IU/ml), ULN Upper limit of normal

*First-line: entecavir, tenofovir
who were co-infected with hepatitis C virus, hepatitis D virus, or human immunodeficiency virus were excluded.

Follow-up
Patients enrolled in the study were followed up once a month within first 3 months. Thereafter, the patients were followed up every 3 months. After 2 years, the patients were followed up every 6 months. At each time-point, blood samples were collected for biochemical and virological parameters examination.

End points, retreatment, and definitions
The main clinical endpoint of this clinical trial was clinical relapse (CR), defined as: HBV DNA > 2000 IU/ml, combined with ALT >2ULN. The patients who experienced clinical relapse were withdrawn from the follow-up study and retreated using NA. The rest of the patients were defined as the non-clinical relapse (NCR) group. The non-clinical relapse group include the virological relapse group and the sustained virological response group. The virological relapse was defined as: HBV DNA > 2000 IU/ml with normal ALT levels.

Laboratory tests
An Olympus AU5400 automatic biochemical analyzer was used for biochemical detection. The ULN of the ALT level was 40 U/L for males and 35 U/L for females. Quantitative analysis of HBV DNA was performed using the Cobas HBV-specific TaqMan polymerase chain reaction assay with a lower limit of detection (LLOD) of 20 IU/ml (Roche Diagnostics, Basel, Switzerland). Serum HBsAg (LLOD, 0.05 IU/ml) and HBeAg quantitation were performed using an Architect Assay (Abbott Laboratories, Chicago, IL). Quantitative total serum anti-HBc (IgG and
IgM) was tested with a double-sandwich immunoassay (Wantai, Beijing, China; LLOD: 0.1 IU/ml) [29].

Enzyme-linked immunosorbent assay (ELISA)
Serum samples were stored at −20 °C after centrifugation until use. The concentration of sST2 was quantitated using a commercial human sST2 ELISA kit (R&D Systems, USA) in accordance with the manufacturer’s instruction.

Statistical analysis
Continuous data are expressed as either the median (minimum - maximum) or the mean ± SEM. An independent samples t test, the Mann-Whitney U test or the Chi square test were used in group comparisons. To examine the dynamic change of sST2 after cessation of long-term NA therapy, the paired T test and the repeated measures ANOVA with Bonferroni test were used to compare the baseline sST2 levels with other different timepoints, and the Mann-Whitney U test was used to compare the sST2 between the CR group and the NCR group at different timepoints. Finally, the Cox proportional hazards regression models to identify factors associated with clinical relapse after stopping long-term NA therapy. All statistical analyses were based on two-tailed hypothesis tests with a significance level of p ≤ 0.05. All statistical analyses were conducted using SPSS 25.0 or GraphPad Prism 8.0 software.

Results
Demographic data and clinical characteristic
In total, 91 non-cirrhotic Asian patients with CHB who stopped NA therapy according to APSAL guidelines

| Variable | Group | CR | NCR | \(\chi^2/Z\) | P |
|----------|-------|----|-----|-------------|---|
| N        |       | 26 | 65  |             |   |
| Gender (M/F) |     | 20/6 | 55/10 | 0.758 | 0.384* |
| Age (years) |     | 39 (25–60) | 35 (18–49) | –2.063 | 0.039² |
| HBV DNA (log10 IU/ml) | | UD | UD | – | – |
| ALT (× ULN) |     | 0.488 (0.30–1.00) | 0.519 (0.15–1.53) | –0.868 | 0.385² |
| HbsAg (log10 IU/ml) | | 2.995 (1.56–4.37) | 2.810 (–2.00–4.14) | –1.805 | 0.071² |
| Anti-Hbc (log10 IU/ml) | | 2.471 (1.51–3.64) | 2.718 (1.21–3.86) | –1.162 | 0.245² |
| Week 4 HBV DNA (log10 IU/ml) | | 0.00 (0.00–5.87) | 0.00 (0.00–5.92) | –3.233 | 0.001² |
| ALT (× ULN) |     | 0.543 (0.25–2.08) | 0.475 (0.20–1.55) | –0.545 | 0.586² |
| HbsAg (log10 IU/ml) | | 2.980 (1.47–4.37) | 2.815 (–2.00–4.13) | –1.651 | 0.099² |
| Anti-Hbc (log10 IU/ml) | | 2.585 (1.41–3.17) | 2.793 (1.21–3.76) | –1.296 | 0.195² |
| Week 12 HBV DNA (log10 IU/ml) | | 3.98 (2.41–8.93) | 2.39 (0.00–5.71) | –5.093 | < 0.001² |
| ALT (× ULN) |     | 0.688 (0.30–18.20) | 0.615 (0.15–1.98) | –1.456 | 0.145² |
| HbsAg (log10 IU/ml) | | 3.125 (2.12–7.5) | 2.760 (–1.70–4.14) | –2.705 | 0.007² |
| Anti-Hbc (log10 IU/ml) | | 3.409 (1.77–4.71) | 2.972 (1.21–4.43) | –1.555 | 0.12² |
| Week 24 HBV DNA (log10 IU/ml) | | 5.99 (4.30–8.93) | 3.110 (0.00–5.73) | –5.432 | < 0.001² |
| ALT (× ULN) |     | 1.074 (0.55–8.40) | 0.550 (0.16–2.03) | –3.929 | < 0.001² |
| HbsAg (log10 IU/ml) | | 3.575 (2.36–4.81) | 2.680 (–2.00–4.19) | –3.756 | < 0.001² |
| Anti-Hbc (log10 IU/ml) | | 3.634 (2.14–4.43) | 3.344 (1.30–4.95) | –2.068 | 0.039² |
| Week 48 HBV DNA (log10 IU/ml) | | 5.66 (0.00–7.95) | 2.880 (0.00–5.87) | –2.391 | 0.017² |
| ALT (× ULN) |     | 3.200 (1.45–7.90) | 0.575 (0.18–1.80) | –2.879 | 0.004² |
| HbsAg (log10 IU/ml) | | 3.450 (2.77–3.45) | 2.695 (–2.00–4.07) | –1.657 | 0.097² |
| Anti-Hbc (log10 IU/ml) | | 4.395 (4.13–4.71) | 3.378 (1.43–4.97) | –3.622 | < 0.001² |

Values are n or median (range)
*Chi - squared test
²Mann -Whitney U-test
M/F Male or female, CR Off-treatment clinical relapse, NCR Non-clinical relapse group; ALT Alanine aminotransferase, HbsAg Hepatitis B surface antigen, HBV Hepatitis B virus, UD Undetectable (< 20 IU/ml), ULN Upper limit of normal
were prospectively followed. At the start of treatment, 61 patients were HBeAg positive, and 30 patients were HBeAg negative. All patients met the withdrawal criteria and signed a withdrawal agreement. The withdrawal time was at least 6 months. The demographic data and clinical characteristics are presented in Table 1.

Clinical relapse and virological relapse after stopping long-term NA therapy

All 91 patients who met the international withdrawal criteria were followed up to 240 weeks. The ratio of clinical relapse, virological relapse, and sustained response at each time point is shown in Fig. 1a. The cumulative virological relapse rate was 80.16% (Fig. 1b), and the cumulative clinical relapse rate was 48.86% (Fig. 1c), which was consistent with previous findings [5–7]. Moreover, it could be found that the majority of virological relapse (61/91, 67.03%) and clinical relapse (26/91, 28.57%) occurred within 48 weeks.

Dynamic change of serum sST2 concentrations after cessation of long-term NA therapy

Then, we examined the concentration of serum sST2 by ELISA in patients after discontinuation of NA therapy for 48 weeks. The CHB patients were divided into CR and NCR group depending on their ALT and HBV DNA levels before week 48. Patients in the CR group were older than those in the NCR group ($p = 0.039$) and had relatively higher end-of-treatment HBsAg levels ($p = 0.071$). Pre-treatment HBeAg status, ALT, and HBV DNA levels no significant differences between CR and NCR group (Table 2). After stop of treatment, the level of the HBV DNA was increased for 24 weeks and slightly decreased during 24–48 weeks in CR group. In the NCR group, HBV DNA
levels have the same trend, but is lower than the CR group at each timepoint (Fig. 2a). ALT levels were significant higher at week 24 and week 48 in CR group than NCR group (Fig. 2b). These results indicated that most patients develop clinical relapse after discontinuation of cessation of NA treatment at earlier time.

We further compared serum sST2 levels in the CR group and NCR group at week 0, week 4, week 12, week 24, and week 48 after discontinuation of NA therapy. There was no significant difference between the two groups at baseline and week 4, and the CR group expressed higher sST2 levels than NCR group at week 12, week 24 and week 48 (Fig. 2c). By using repeated measures ANOVA analysis, we only observed the significant difference of serum sST2 levels in the CR group between week 48 and week 12 ($p = 0.004$), week 48 and week 0 ($p = 0.007$), respectively. Further compared with the baseline at the end of treatment, sST2 expression was increased at clinical relapse timepoint in CR group ($p < 0.001$), while there was no significant difference between baseline and 48 W sST2 in the NCR group (Fig. 2d).

**Serum sST2 expression is positively correlated with HBsAg, ALT, HBV DNA and anti-HBc levels**

Pearson analysis was used to evaluate the association between serum sST2 with HBsAg, ALT, HBV DNA and anti-HBc levels in patients after discontinuation of NA treatment. As shown in Fig. 3, there were positive correlations between serum sST2 levels and HBsAg ($r = 0.2055$, $p < 0.0001$, Fig. 3a), ALT ($r = 0.1953$, $p < 0.0001$, Fig. 3b), HBV DNA ($r = 0.2562$, $p < 0.0001$, Fig. 3c), and anti-HBc levels ($r = 0.2068$, $p < 0.0001$, Fig. 3d).
Fig. 3b), HBV DNA \((r = 0.2562, p < 0.0001, \text{Fig. 3c})\) and anti-HBc \((r = 0.2068, p < 0.0001, \text{Fig. 3d})\). These data further suggested that sST2 expression might be associated with liver inflammation caused by virus replication rebound during clinical relapse.

**Baseline sST2 expression could not predict clinical relapse after stopping of NA treatment**

To elucidate whether serum sST2 levels at the end of treatment were associated with clinical relapse follow-up to 240 weeks, univariate and multivariate Cox regression analyses were conducted. As shown in Table 3, the age > 35 y \((p = 0.006; \text{hazard ratio [HR]}: 2.647, 95\% \text{confidence interval [CI]}: 1.324–5.291)\), HBsAg > 200 IU/ml \((vs \leq 200 \text{IU/ml}) (p = 0.006; \text{HR}: 3.697, 95\% \text{CI}: 1.447–9.444)\), HBV DNA level elevation > 20000 IU/ml \((vs \leq 20000 \text{IU/ml}) (p = 0.017; \text{HR}: 2.531, 95\% \text{CI}: 1.179–5.435)\) and the levels of sST2 at week 12 \((p < 0.001; \text{HR}: 4.655, 95\% \text{CI}: 2.345–9.243)\) were found to be independent predictors for clinical relapse in off-treatment CHB patients. The baseline serum sST2 expression was not statistically significant to be an independent predictor of clinical relapse. However, we could observe a HR of 1.718 in the factor of sST2, indicating that the risk of clinical relapse is 1.718 times higher in patients with elevated sST2 than in patients with non-elevated sST2.

**Discussion**

In this prospective follow-up study of Asian patients with CHB who stopped NA therapy, we demonstrated that the cumulative rate of virological relapse was higher than the cumulative rate of clinical relapse (80.16% vs 48.86%). Moreover, most patients occurred virological recurrence or clinical recurrence within 48 weeks. This observation might be due to that the NA therapy, regardless of differences in antiviral potency, only has a small effect on levels of intrahepatic cccDNA. As the template for HBV RNA transcription, residual cccDNA pool or integrated viral DNA produced viral RNA continuously and viral DNA replication was recovery in infected hepatocytes after cessation of long-term NA therapy [5, 7, 30, 31]. Therefore, a high rate of virologic rebound was observed in HBsAg positive patients after discontinuation of NA treatment. To avoid rebound of HBV DNA after stopping NA therapy, the best stopping

| Table 3 Cox proportional hazards regression analysis of clinical relapse |
|-----------------------------------------------|
| Clinical Relapse (n = 41) | Univariable | Multivariable a |
| | HR | 95% CI | P | HR | 95% CI | P |
| End of treatment | | | | | | |
| Age | 1.069 | 1.025–1.114 | 0.002 | 1.062 | 1.016–1.110 | 0.007 |
| Age > 35 y | 2.647 | 1.324–5.291 | 0.006 | | | |
| Sex | 1.44 | 0.662–3.133 | 0.358 | | | |
| First-line NA therapy b | 1.233 | 0.667–2.281 | 0.504 | | | |
| Consolidation duration | 0.996 | 0.980–1.011 | 0.596 | | | |
| Consolidation duration 3 > y | 0.777 | 0.401–1.508 | 0.456 | | | |
| ALT x ULN | 0.861 | 0.331–2.241 | 0.759 | | | |
| HBsAg log10 IU/ml | 1.1725 | 1.177–2.529 | 0.005 | 2.086 | 1.286–3.385 | 0.003 |
| HBsAg > 200 IU/ml (vs ≤ 200 IU/ml) | 3.697 | 1.447–9.444 | 0.006 | | | |
| HBV DNA level elevation log10 IU/ml | 1.000 | 1.000–1.000 | 0.030 | 1.000 | 1.000–1.000 | 0.045 |
| HBV DNA level elevation > 20000 IU/ml (vs ≤ 20000 IU/ml) | 2.531 | 1.179–5.435 | 0.017 | | | |
| sST2 log10 pg/mL | 2.816 | 0.731–10.845 | 0.132 | | | |
| sST2 > 3.7 log10 pg/mL (vs ≤ 3.7 log10 pg/mL) | 1.718 | 0.841–3.508 | 0.137 | | | |
| 12W sST2 log10 pg/mL | 4.655 | 2.345–9.243 | < 0.001 | 4.403 | 2.169–8.937 | < 0.001 |
| Start of treatment | | | | | | |
| HBsAg | 0.726 | 0.384–1.375 | 0.326 | | | |
| ALT x ULN | 0.986 | 0.935–1.019 | 0.403 | | | |
| HBV DNA log10 IU/ml | 0.745 | 0.792–1.385 | 0.745 | | | |

Abbreviations: ALT Alanine aminotransferase, CI Confidence interval, HBsAg Hepatitis B virus surface antigen, HBV Hepatitis B virus, HR Hazard ratio, NA Nucleos(t)ide analogue, ULN Upper limit of normal

aAdjusted for start-of-treatment HBsAg status and factors that were statistically different between HBsAg-positive and HBsAg-negative patients (age and consolidation therapy duration)
bEntecavir
criterion might be HBsAg seroclearance, which referred to host immune control of infection [32].

It had been suggested that a relapse, resulting in increased HBV replication, could change the cytokine milieu and lead to increased responsiveness of HBV-specific T cells and NK cells at 12 weeks after stopping long-term NA treatment [33, 34]. Thus, the inflammation-associated cytokines, which correlated with the activation of host immune system, were elevated at 12 weeks after discontinuation of NA treatment [35]. In murine inflammatory models, the expression of ST2 is induced by proinflammatory stimuli [36, 37]. We found that serum sST2 was positively correlated with HBsAg, HBV DNA, ALT and anti-HBc levels. Therefore, an early virological rebound might be accompanied with a transient increase in ALT and an elevation of sST2 expression after discontinuation of the NA therapy. In addition, serum sST2 levels in the CR group were found to be higher than in the NCR group after discontinuation of NA treatment. Moreover, the level of sST2 at the point of clinical relapse was significantly higher than the sST2 levels at baseline. These results were consistent with previous findings that serum ST2 levels were significant higher in CHB patients than in healthy controls [38], and ST2 levels are positively correlated with ALT in immune active CHB patients [24].

Identifying the useful biomarker to predict clinical relapse after stopping long-term NA therapy remained to be a challenge for management of CHB patients. By Cox proportional hazards regression analysis, we confirmed that age and baseline HBsAg levels were factors that affecting clinical relapse, which was consistent with previous findings [39]. However, baseline sST2 expression was not an independent predictor of clinical relapse. Interestingly, the levels of sST2 at week 12 can predict the clinical relapse after stopping NA therapy. It has been shown that the host immunity, including innate and adaptive immune responses, played an important role in the control and resolution of chronic HBV infections [40]. Thus, whether HBV specific immune biomarkers could be used for prediction of clinical relapse needed further investigation.

There were some limitations to the current study. Firstly, the number of cases included in the current study is relatively small, with a total of 91 cases, and there is a need to further expand the sample size in future research. Secondly, the source of elevated sST2 expression and the function of sST2 in chronic HBV infection were not studied in this study by in vitro cell culture system. Finally, serum sST2 levels showed an upward trend in the CR group and were higher at the point of clinical relapse than at baseline, but not in the NCR group. The specific mechanism underlying this phenomenon remained to be clarified in the future.

Conclusions
The incidence of virological relapse and clinical relapse was high in CHB patients after stopped NA therapy. The increase of sST2 in clinical relapse patients might be associated with an inflammation-related immune response after discontinuation of NA treatment.

Abbreviations
ALT: Alanine aminotransferase; anti-HBc: Hepatitis B core antibody; cccDNA: covalently closed circular DNA; CHB: Chronic hepatitis B; HBsAg: Hepatitis B virus surface antigen; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; LLOD: Lower limit of detection; NA: Nucleos(t)ide analogue; sST2: Soluble growth stimulation expressed gene 2; ULN: Upper limit of normal

Acknowledgements
We are grateful to the patients whom enrolled in this study, the nurses whom assisted in the patient management and the collection of blood samples.

Authors’ contributions
XZ and HL conceived and designed the study. LX, GL, HC, MX, XH and RF collected the demographic data, performed the experiments and analyzed the data. XZ, LX and JP performed statistical analysis, and participated in the interpretation of data and writing manuscript. All authors critically reviewed and approved the final manuscript.

Funding
This work was partly supported by grants from the National Natural Science Foundation of China (81971664), National Science and Technology Major Project of China (2018ZX10301202–003) and the Collaboration and Innovation Health Care Major Project of Guangzhou (201803040013). The funding bodies had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials
The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.

Ethics approval and consent to participate
This study was conducted in compliance with the Declaration of Helsinki and approved by the Ethical Committee of Nanfang Hospital (N FEC-201209-K3). All patients provided written documentation of informed consent to enter the study.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
2Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, 1938 Guangzhou Avenue North, Guangzhou 510515, China.

Received: 5 September 2018 Accepted: 4 July 2019
Published online: 19 July 2019

References
1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212–9.
2. EASL. 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98.
10. Pan X, Zhang K, Yang X, Liang J, Su M, Li X, et al. Relapse rate and associated-factor of recurrence after stopping NUCs therapy with different prolonged consolidation therapy in HBsAg positive CHB patients. PLoS One. 2013;8(7):e66586.

11. Jiang JN, Huang ZL, He LX, Huang YH, Su MH, Xie R, et al. Residual amount of HBV DNA in serum is related to relapse in chronic hepatitis B patients after cessation of nucleos(t)ide analogs. J Clin Gastroenterol. 2015;49(4):323–8.

12. Shinkai N, Tanaka Y, Orito E, Ito K, Ohno T, Hirashima N, et al. Measurement of HBV virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection. Hepatol Res. 2006;36(4):272–6.

13. Sung JY, Wong M, Bowden S, Liew C, Hui AY, Wong WS, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology. 2005;128(7):1890–7.

14. Miller AM, Liew FY. The IL-33/ST2 pathway—a new therapeutic target in cardiovascular disease. Pharmacol Ther. 2011;131(2):179–86.

15. Kunes P, Holubcova Z, Kolackova M, Krejsek J. Interleukin-33, a novel member of the IL-1/IL-18 cytokine family, in cardiology and cardiac surgery. Thorac Cardiovasc Surg. 2010;58(8):443–9.

16. Li H, Tago K, Ko Koriuwa K, Arai T, Iwahana H, et al. The cloning and nucleotide sequence of human ST2L CDNA. Genomics. 2000;67(3):284–90.

17. Oshikawa K, Koriuwa K, Tago K, Iwahana H, Yanagisawa K, Ohno S, et al. Elevated soluble ST2 protein levels in sera of patients with asthma as an acute exacerbation. Am J Respir Crit Care Med. 2001;164(2):277–81.

18. Ali M, Zhang G, Thomas WR, McLean CJ, Bizzineto JA, Liang IA, et al. Investigations into the role of ST2 in acute asthma in children. Tissue Antigens. 2009;73(3):205–12.

19. Shimizu M, Matsuda A, Yanagisawa K, Hirata T, Akahoshi M, Inomata N, et al. Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis. Hum Mol Genet. 2005;14(19):2919–27.

20. Hong Y, Moon S, Joo Y, Jeon C, Cho M, Ju JH, et al. Measurement of Interleukin-33 (IL-33) and IL-33 receptors (ST2 and ST2L) in patients with rheumatoid arthritis. J Korean Med Sci. 2011;26(9):1152.

21. Talbot-Ayer D, McKee T, Ginde P, Bas S, Baeten DL, Gabay C, et al. Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine. 2012;79(1):32–7.

22. Díaz-Jiménez D. Soluble ST2: a new and promising activity marker in ulcerative colitis. World J Gastroenterol. 2011;17(7):2181.

23. Mok MY, Huang FP, Ip WK, Lo Y, Wong FY, Chan ETY, et al. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology. 2010;49(3):520–7.

24. Huan SL, Zhao JG, Wang ZL, Gao S, Wang K. Relevance of serum interleukin-33 and ST2 levels and the natural course of chronic hepatitis B virus infection. BMC Infect Dis. 2016;16:200. https://doi.org/10.1186/s12879-016-1543-x.

25. Jiang SW, Wang P, Xiang XG, Mo RD, Lin LY, Bao SS, et al. Serum soluble ST2 is a promising prognostic biomarker in HBV-related acute-on-chronic liver failure. Hepatobiliary Pancreat Dis Int. 2017;16(2):181–8.

26. Chi H, Li Z, Hansen BE, Yu T, Zhang X, Sun J, et al. Serum level of antibodies against hepatitis B Core protein is associated with clinical relapse after discontinuation of Nucleos(t)ide analogue therapy. Clin Gastroenterol H. 2019;17(1):82–91.

27. Peng J, Cao J, Yu T, Cai S, Li Z, Zhang X, et al. Predictors of sustained virologic response after discontinuation of nucleos(t)ide analog treatment for chronic hepatitis B. Saudi J Gastroenterol. 2015;21(4):245.

28. Liaw YF, Kao JH, Pratihast T, Chan HL, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6(4):531–6.

29. Li A, Yuan Q, Huang Z, Fan J, Guo R, Lou B, et al. Novel double-antigen Sandwich immunoassay for human hepatitis B Core antibody. Clin Vaccine Immunol. 2010;17(3):464–9.

30. Liang Y, Jiang J, Su M, Liu Z, Guo W, Huang X, et al. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. Aliment Pharm Ther. 2011;34(3):344–52.

31. Hadzyiannakis SJ, Sebastianios V, Raptopoulos D, Hadzyiannis E. Sustained responses and loss of HBsAg in HBsAg-negative patients with chronic hepatitis B who stop long-term treatment with Adefovir. Gastroenterology. 2012;143(4):1325–32.

32. Kim G, Lim Y, An J, Lee D, Shim JH, Kim KM, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut. 2014;63(8):1329–36.

33. Zimmer CL, Rinker F, Sierderssen C, Manns MP, Kraft A, Wedemeyer H, et al. HBsAg virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBsAg negative chronic hepatitis B. J Hepatol. 2018;69(3):584–93.

34. Rinker F, Zimmerman CL, Sierderssen C, Manns MP, Wedemeyer H, Comberg M, et al. Increased NK cell function after cessation of long-term Nucleos(t)ide analogue treatment in chronic hepatitis B is associated with liver damage and HBsAg loss. J Infect Dis. 2018;217(10):1656–66.

35. Höner Zu Siederdissen C, Rinker F, Maasoumy B, Wiegand SB, Finkmann N, Falk CS, et al. Viral and host responses after stopping long-term Nucleos(t)ide analogue therapy in HBsAg-negative chronic hepatitis B. J Infect Dis. 2016;214(10):1492–7.

36. Kumar S, Tzimas MN, Griswold DE, Young PR. Expression of ST2, an Interleukin-1 receptor homologue, is induced by Proinflammatory stimuli. Biochem Biophys Res Commun. 1997;235(3):474–8.

37. Oshikawa K, Yanagisawa K, Tominaga S, Sugiyama Y. ST2 protein induced by inflammatory stimuli can modulate acute lung inflammation. Biochem Biophys Res Commun. 2002;299(1):18–24.

38. Wang J, Cai Y, Ji H, Feng J, Ayana DA, Niu J, et al. Serum IL-33 levels are correlated with plasma levels of C-reactive protein in patients with acute heart failure. Biomed Res Int. 2014;2014:1456653.

39. Lee C, Ong G, Lu S, Wang J, Liao C, Tung H, et al. Durability of lamivudine-induced HBsAg serocconversion for chronic hepatitis B patients with acute exacerbation. J Hepatol. 2002;37(5):669–74.

40. Zhu W, Liu H, Zhang X. Toward Curative Immunomodulation Strategies for Chronic Hepatitis B Virus Infection. ACS Infect Dis. 2019;5(5):703–12.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.